Multi-omics and machine learning integration of diverse cell death pathways optimize risk stratification and inform drug therapy in Wilms tumor
Authors:
Open Access
- 9 June 2026
- journal article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Despite significant improvements in the overall survival of Wilms tumor (WT), a subset of patients still experiences poor outcomes. Programmed cell death (PCD) pathways are pivotal in cancer progression. A deeper understanding of their roles in WT is crucial for harnessing these mechanisms to optimize risk stratification. Key tumor-associated genes were identified through limma differential analysis and WGCNA, and subsequently integrated with 12 distinct PCD patterns. TARGET-WT transcriptomic data was divided into training and validation sets to construct and validate a risk stratification model. It was subsequently integrated with clinical information to build a comprehensive prediction model. Immune infiltration and drug sensitivity analyses were performed. External validation was performed using scRNA-seq data from GSE200256. Key tumor-associated genes were enriched in multiple PCD pathways. The risk stratification model was constructed using 4 genes selected via the machine learning algorithm, stratifying the cohort into high- and low-risk groups. In the overall WT cohort, the high-risk group exhibited worse prognosis, with 1-, 3-, and 5-year AUC values of 0.820, 0.721, and 0.728, respectively. DCA demonstrated the superior predictive accuracy of the comprehensive prediction model. The high-risk group showed lower infiltration of TH17 cells and increased sensitivity to paclitaxel and sorafenib. Finally, the expression landscape of hub genes was validated in the single-cell dataset. These results highlight a critical role for PCD genes in the progression and immune regulation of WT. Targeting these genes offers a promising avenue for improving clinical management of patients identified as high-risk.Keywords
All Related Versions
Funding Information
- Key Research and Development Program of Heilongjiang (2022ZX06C08)
This publication has 60 references indexed in Scilit:
- Systematic pan-cancer analysis identifies DNASE2 as a potential prognostic marker and immunotherapeutic target for glioblastoma multiformeGenes & Diseases, 2025
- Correlation between HMGB1 expression and drug resistance and prognosis in patients with bladder urothelial carcinomaDiscover Oncology, 2025
- Advances in the clinical management of high‐risk Wilms tumorsPediatric Blood & Cancer, 2023
- Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgeryInternational Journal of Surgery, 2022
- Cytoplasmic DNA in cancer cells: Several pathways that potentially limit DNase2 and TREX1 activitiesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2022
- Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meetingEuropean Journal of Cancer, 2021
- ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer ImmunotherapyAdvanced Science, 2020
- The release and activity of HMGB1 in ferroptosisBiochemical and Biophysical Research Communications, 2019
- Biology and treatment of renal tumours in childhoodEuropean Journal of Cancer, 2016
- Estimating and comparing time‐dependent areas under receiver operating characteristic curves for censored event times with competing risksStatistics in Medicine, 2013